| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID665899 | Half life in rat at 2 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665889 | Inhibition of CYP2D6 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665921 | Antiobesity activity in po dosed fasted rat assessed as reduction in TAG to DAG ratio in adipose tissue | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665909 | Antiobesity activity in fasted rat assessed as reduction in plasma triacylglycerol excursion at 0.03 mg/kg, po administered 2 hrs prior to bolus dose of corn oil measured after 1.5 hrs by OLTT | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665895 | Cmax in mouse at 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665882 | Fraction unbound in rat plasma | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665883 | Apparent permeability across apical to basolateral side in MDCK cells at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665917 | Antiobesity activity in DIO mouse assessed as reduction in body weight at 20 mg/kg, po bid for 3 days | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665912 | Antiobesity activity in po dosed fasted rat assessed as reduction in plasma triacylglycerol excursion administered 2 hrs prior to bolus dose of corn oil measured after 1.5 hrs by OLTT | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665886 | Inhibition of CYP1A2 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665879 | Inhibition of mouse DGAT1 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665894 | Half life in mouse at 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665893 | Half life in mouse at 0.5 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665902 | Oral bioavailability in rat at 5 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665898 | Volume of distribution at steady state in rat at 2 mg/kg, iv and 5 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665873 | Inhibition of human recombinant DGAT1 expressed in baculovirus infected insect sf9 cells using [14C] oleoyl coenzyme A after 30 mins by scintillation counting | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665903 | Plasma clearance in dog at 1 mg/kg, iv and 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665880 | Inhibition of DGAT1-mediated triacylglycerol synthesis in human HuTu80 cells | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665885 | Inhibition of human Erg | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665914 | Antiobesity activity in fasted rat assessed as reduction in TAG to DAG ratio in adipose tissue at 0.3 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665911 | Antiobesity activity in fasted rat assessed as reduction in plasma triacylglycerol excursion at 0.2 mg/kg, po administered 2 hrs prior to bolus dose of corn oil measured after 1.5 hrs by OLTT | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665905 | Half life in rat at dog at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665892 | Volume of distribution at steady state in mouse at 0.5 mg/kg, iv and 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665907 | Cmax in dog at 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665906 | Half life in dog at 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665915 | Antiobesity activity in fasted rat assessed as reduction in TAG to DAG ratio in adipose tissue at 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665904 | Volume of distribution at steady state in dog at 1 mg/kg, iv and 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665875 | Lipophilicity, log D of the compound | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665900 | Half life in rat at 5 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665913 | Antiobesity activity in fasted rat assessed as reduction in TAG to DAG ratio in adipose tissue at 0.1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665896 | Oral bioavailability in mouse at 1 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665901 | Cmax in rat at 5 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665884 | Apparent permeability across basolateral to apical side in MDCK cells at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665877 | Aqueous solubility of the compound at pH 7.4 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665881 | Fraction unbound in human plasma | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665919 | Antiobesity activity in DIO mouse assessed as reduction in food intake at 20 mg/kg, po bid for 3 days | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665918 | Antiobesity activity in lean mouse assessed as reduction in body weight at 20 mg/kg, po bid for 3 days | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665887 | Inhibition of CYP2C9 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665897 | Plasma clearance in rat at 2 mg/kg, iv and 5 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID1154993 | Inhibition of human DGAT1 expressed in Sf9 insect cells using 1,2-dioleoyl-sn-glycerol and [14C]-palmitoyl-CoA substrate by scintillation counting analysis | 2014 | ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
| Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors. |
| AID665908 | Oral bioavailability in dog at 1 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665890 | Inhibition of CYP3A4 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665874 | Inhibition of DGAT2 expressed in baculovirus infected insect sf9 cells using [14C] oleoyl coenzyme A at 10 uM after 30 mins by scintillation counting | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665878 | Inhibition of rat DGAT1 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665916 | Antiobesity activity in fasted rat assessed as reduction in TAG to DAG ratio in adipose tissue at 3 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID1129956 | Inhibition of human DGAT1 | 2014 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
| Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors. |
| AID665910 | Antiobesity activity in fasted rat assessed as reduction in plasma triacylglycerol excursion at 0.1 mg/kg, po administered 2 hrs prior to bolus dose of corn oil measured after 1.5 hrs by OLTT | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665888 | Inhibition of CYP2C19 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| AID665891 | Plasma clearance in mouse at 0.5 mg/kg, iv and 1 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |